), which were not statistically different from BAS clinical trials (P>0.05). Conclusions-The cholesterol lowering effect of BAS may translate into a clinically relevant reduction in CAD.
levated plasma levels of low-density lipoprotein cholesterol (LDL-C) are a well-established risk factor of cardiovascular disease (CVD). 1 Current guidelines recommend that statin therapy should be used in select groups of patients with atherosclerotic CVD in primary and secondary prevention settings. 2 However, statins may not be fully effective in lowering LDL-C 3, 4 or well tolerated, 5 and therefore, patients may require additional or alternative lipid-lowering treatments.
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Bile acid sequestrants (BAS) are large polymers that bind to bile salts in the small intestine, preventing their reabsorption into the enterohepatic circulation pathway. The resulting depletion of bile acids leads to increased hepatic metabolism of cholesterol for bile salt synthesis, thereby lowering plasma LDL-C levels. 6 Three BAS have been approved for clinical use: cholestyramine and colestipol (first generation) and colesevelam hydrochloride (colesevelam; second generation). Colesevelam was developed to overcome gastrointestinal intolerance associated with the first-generation BAS. [7] [8] [9] Three randomized controlled trials (RCTs) have evaluated the efficacy of cholestyramine for cardiovascular prevention, but results have been inconclusive. 8, 10, 11 Although most of these trials have demonstrated that treatment with cholestyramine Background-Statins lower low-density lipoprotein cholesterol (LDL-C) and risk of coronary artery disease (CAD), but they may be ineffective or not tolerated. Bile acid sequestrants (BAS) reduce LDL-C, yet their clinical efficacy on CAD remains controversial. Methods and Results-We conducted a systematic review and meta-analysis of randomized controlled trials to assess the effect of cholestyramine and colesevelam. We then used Mendelian randomization to estimate the effect of BAS on reducing the risk of CAD. First, we quantified the effect of rs4299376 (ABCG5/ABCG8), which affects the intestinal cholesterol absorption pathway targeted by BAS and then we used these estimates to predict the effect of BAS on CAD.
Nineteen randomized controlled trials with a total of 7021 study participants were included. Cholestyramine 24 g/d was associated with a reduction in LDL-C of 23.5 mg/dL (95% confidence interval [CI] −26.8,−20.2; N=3806) and a trend toward reduced risk of CAD (odds ratio 0.81, 95% CI 0.70-1.02; P=0.07; N=3806), whereas colesevelam 3.75 g/d was associated with a reduction in LDL-C of 22.7 mg/dL (95% CI −28.3, −17.2; N=759). Based on the findings that rs4299376 was associated with a 2.75 mg/dL decrease in LDL-C and a 5% decrease in risk of CAD outcomes, we estimated that cholestyramine was associated with an odds ratio for CAD of 0.63 (95% CI 0.52-0.77; P=6.3×10 −6 ) and colesevelam with an odds ratio of 0.64 (95% CI 0.52-0.79, P=4.3×10 −5 reduces LDL-C levels, only one trial has shown a modest reduction in the risk of CVD events (odds ratio [OR] 0.81, 95% CI 0.70-1.02; P=0.07). 8 To date, there are no adequately powered trials exploring the effects of colesevelam or colestipol on the risk of major cardiovascular events. Thus, the efficacy of BAS in the prevention of CVD is uncertain.
Mendelian randomization analyses use genetic variants with a known biological function to explore the effects of a modifiable exposure on an outcome. 12, 13 Genetic variants are useful instruments for assessing causality because they are randomly allocated and they are independent of many factors that may confound observational associations. Thus, in the absence of evidence from randomized trials, the principles of Mendelian randomization can be applied for drug target validation because functional alleles of a gene within a drug target pathway can be used to extrapolate the effects of the pharmacological intervention. 14, 15 This approach can strengthen the rationale for conducting an RCT 12 because it is highly costeffective as a result of the availability of genetic data through large-scale biobanks and data consortia.
The ATP-binding cassette (ABC) genetic subfamily forms active membrane transporters that regulate the delivery and disposal of intestinal cholesterol and affects the same pathway that is targeted by BAS. 16 The ABC subfamily G member 5 (ABCG5) and ABCG8 genes are mainly expressed in hepatocytes and enterocytes. 17 In the liver, these transporter genes are responsible for increased biliary cholesterol secretion, whereas in the intestine, they recycle free cholesterol from the enterocyte back into the intestine lumen and promote the fecal excretion of biliary sterols. 18 The rs4299376 single nucleotide polymorphism (SNP) is an intronic variant of ABCG8 ( Figure I in the Data Supplement). This SNP has been associated with altered plasma LDL-C levels [19] [20] [21] and risk of coronary artery disease (CAD) in the CARDIoGRAMplusC4D Consortium. 22 Based on this evidence and the observation that both the ABCG5/8 heterodimer and BAS target intestinal sterol absorption and excretion, the rs4299376 SNP represents a suitable proxy for the mechanism-based effect of BAS on LDL-C and the risk of CVD.
To test whether BAS has the potential to reduce the risk of cardiovascular outcomes, we first conducted a systematic review and meta-analysis to assess the effect of BAS on plasma lipid levels and major cardiovascular outcomes. We then applied principles of Mendelian randomization to predict the effect of BAS on CAD using the known genetic association of the ABCG5/ABCG8 polymorphism rs4299376 with lipids 23 and CAD.
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Methods
Search Strategy and Study Selection of Clinical Trials
A structured search of RCTs evaluating the effects of BAS on markers of cardiovascular risk or clinical outcomes was conducted in the PubMed database. The following terms were used to search all clinical trial registries and databases: colesevelam; cholestyramine; colestipol; placebo; and randomized controlled trials. Only studies with a double-blinded, placebo-controlled trial design in adults aged 18 years that assessed the effect of BAS (ie, cholestyramine, colestipol, and colesevelam) in comparison with a placebo were included.
Refer to Methods in the Data Supplement for more details.
Global Lipids Genetics Consortium
Data on the genetic association between the rs4299376 SNP and plasma lipid levels were obtained from a previously published genomewide association study. In brief, Teslovich et al (2011) performed a meta-analysis of 46 lipid genome-wide association study assessing common variants associated with serum lipids (LDL-C, high density lipoprotein cholesterol (HDL-C), total cholesterol (TC), and triglycerides). 23 A total of 46 studies and 91 285 individuals of European descent were analyzed for the genetic association with LDL-C, whereas data from 95 708, 95 992 and 92 410 individuals were available for HDL-C, TC, and triglycerides, respectively.
CARDIoGRAMplusC4D Consortium
Data on the genetic association between the rs4299376 SNP (ABCG5/8) and the risk of CAD was obtained from the CARDIoGRAMplusC4D Consortium. Briefly, the CARDIoGRAMplusC4D Consortium performed a meta-analysis of 63 746 cases of CAD and 130 681 controls. 22 CAD outcomes were defined as one of the following: myocardial infarction (MI), >50% stenosis in at least one coronary vessel at angiography, history of percutaneous transluminal coronary angioplasty or coronary artery bypass graft surgery, angina, or death caused by CAD. 24 For the association between the rs4299376 SNP and CAD outcomes, the lipid-lowering allele was used as reference throughout the article.
Cholesterol Treatment Trialists' Collaboration
As a sensitivity analysis, we confirmed the predicted effect of BAS on CAD using data from the Cholesterol Treatment Trialists' (CTT) Collaboration. 25 Briefly, the CTT was a prospective meta-analysis of 169 138 individuals from 26 statin RCTs that assessed the association between the change in LDL-C with statin therapy and the reduction in risk of CVD. Over a period of 5 years, there were a total of 24 323 major vascular events, which was defined as the first occurrence of coronary death or nonfatal MI, coronary revascularization, or stroke.
Statistical Analysis
To calculate the effect of BAS on plasma lipids levels, the mean change-from-baseline of plasma lipids in the 24 g/d cholestyramine treatment group and the 3.75 g/d colesevelam group were compared with the mean differences in the placebo group. Meta-analyses were performed using an inverse variance random effect meta-analysis. Unless otherwise specified, a correlation coefficient (r) of 0.5 for the difference in the mean change from baseline was assumed for all analyses. Thus, the r was varied by 0.3 and 0.7 for all the relevant studies to determine whether this altered the reported estimates (Figures II-V in the Data Supplement). Refer to Methods in the Data Supplement for further details.
Simulations were performed to predict the effect of 24 g/d cholestyramine on plasma lipid profiles (HDL-C, TC, and triglycerides) using the known genetic associations of rs4299376 SNP with lipids fractions. To do so, we adapted the method from Sofat et al 14 to match the genetic effects to the effect of cholestyramine 24 g/d on LDL-C, taking into account the uncertainty of both the genetic and drug effect estimates. Refer to Methods in the Data Supplement for more information. To validate whether the rs4299376 SNP had a similar effect on plasma lipid profiles as cholestyramine, the predicted effects of cholestyramine on plasma levels of HDL-C, TC, and triglycerides were estimated using genetic data. These predicted estimates were then compared with known effects of cholestyramine on the same lipids fractions from clinical data. Next, the predicted effect of cholestyramine on the risk of cardiovascular outcomes was projected using data from the genetic association of rs4299376 with CAD. This was then compared with the effect of cholestyramine on CAD from the only outcome trial of cholestyramine, Lipid Research Clinics Coronary Primary Prevention Trial (LRCCPPT).
8 Figure 1 represents the schematic representation of the Mendelian randomization design. As a sensitivity analysis, the predicted effect of cholestyramine on CAD was also estimated using data from the CTT, 25 a large meta-analysis that assessed the effect of statin therapy on the risk of CVD outcomes among 5 trials that compared more intensive to less intensive statin therapy (N=39 612) and 21 trials that compared statin to a control (N=129 526). This estimate was similarly compared with the effect of BAS on cardiovascular outcomes reported in the LRCCPPT, thus testing whether the effect of BAS on reduction of CAD event was consistent with the one observed with statins, after taking into account the differences in LDL-C lowering efficacy. The same analyses were performed for 3.75 g/d colesevelam. Refer to Methods in the Data Supplement for more information. All statistical analyses were performed using R.
Results
Study Selection
The structured literature search of PubMed databases derived a total of 420 citations, and 19 studies were identified for inclusion in this review. Figure VI in the Data Supplement contains a flow diagram of the study selection process. Owing to the lack of reported data from clinical trials, the results of the colestipol meta-analysis are described in Methods in the Data Supplemental and Table I in the Data Supplement.
Randomized Controlled Trials of Cholestyramine
We identified a total of 6 RCTs comprising 4598 hyperlipidemia participants. 8, 10, 11, [26] [27] [28] The mean age of these study participants was 48.2 years, whereas 4.8% were female and 95% were European (Table) . In the pooled analysis of plasma lipid levels, 3 RCTs evaluated the effect of 24 g of cholestyramine daily dose compared with matching placebo in 4002 hyperlipidemia patients (Figure 2 ). The pooled estimates indicate that cholestyramine treatment resulted in a mean decrease of LDL-C by 53.4 mg/dL (95% CI −91.8, −15.0) and a decrease of TC by 50.7 mg/dL (95% CI −89.9, −11.5). There was significant heterogeneity among the pooled changes in LDL-C (I 2 93.3% and P for heterogeneity, 5.4×10 −6 ) and TC (I 2 93.5% and P for heterogeneity, 9.1×10 −6 ). 
Randomized Controlled Trials of Colesevelam
We identified 10 trials with a total of 1142 participants with hyperlipidemia and 883 participants with type 2 diabetes mellitus. 20, [29] [30] [31] [32] [33] [34] [35] [36] [37] Among all of these participants, the average age was 55.5 years, 51% were women, and 62% were European (Table) . Seven RCTs comprising 767 study participants evaluating the effect of colesevelam 3.75 g daily compared with matching placebo were used in the primary analysis ( Figure 3) . Treatment with colesevelam resulted in a mean decrease of LDL-C by 22.7 mg/dL (95% CI −28.3, −17.2) with significant heterogeneity among the pooled change in LDL-C (I 2 56.95% and P for heterogeneity, 0.032). Colesevelam treatment was also associated with a decrease in TC by 19. . We were unable to conduct subgroup analyses to explore the presence of heterogeneity among pooled estimates owing to a lack of data. , and data for this association was obtained from RCTs that assessed the effect of BAS compared with a placebo. Association 3 represents the genetic effect of rs4299376 on change in LDL-C, and data for this association was obtained from the Global Lipids Genetics Consortium. Association 4 represents the genetic effect of rs4299376 on the risk of CAD, and data for this association was obtained from the CARDIoGRAMplusC4D Consortium. CVD indicates cardiovascular disease.
Predicted Effects of BAS on Plasma Lipids Using Genetic Data
Teslovich et al (2010) confirmed the association between the rs4299376 SNP and plasma lipid levels. 23 The rs4299376
polymorphism was significantly associated with a decrease in LDL-C of 2.75 mg/dL per allele (95% CI −3.14, −2. 
212).
We also explored whether the rs4299376 SNP had potential pleiotropic effects on the risk of diabetes mellitus or on the change in glycohemoglobin (HbA 1c ), fasting glucose, systolic blood pressure, diastolic blood pressure, and body mass index using data from the DIAGRAM, 38 MAGIC, 39, 40 GIANT, 41 and ICBP 42 consortia. We did not observe any significant changes among these traits (P>0.05 for all; Figure 4 ; Table II in the Data Supplement). Next, we sought to determine whether the predicted effect of BAS using genetic data had a similar effect on plasma lipids levels as compared with the reported pharmacological effect. To do so, we adjusted the per-allele genetic effect to match the LDL-C reducing effect of 24 g/d cholestyramine, as reported in the LRCCPPT trial 8 (the only BAS outcome trial available). We then predicted the effect of cholestyramine on TC using genetic data and compared it to the known effect of cholestyramine. The predicted reduction of TC was 25.8 mg/dL (95% CI −32.3, −19.4), which was not statistically different from the reported trial estimate (P for difference >0.05).
We performed a similar analysis using the effect of colesevelam 3.75 g/d on LDL-C as the reference for the genetic effect ( Figure 5 ). The predicted reduction of TC by colesevelam was estimated at 25.0 mg/dL (95% CI −33.0, −16.9), which was not different (P>0.05) from results of our metaanalysis. The predicted effect on HDL was null (0.42 mg/dL, 95% CI −0.78, 1.61) and was consistent with the reported effect of colesevelam (P for difference >0.05). The predicted effect of colesevelam was associated with a modest decrease in triglycerides (8.94 mg/dL [95% CI: −15.5, −2.32] and was statistically different from the observed drug effect (P for difference, 0.001).
Predicted Effects of BAS on Cardiovascular Outcomes Using Genetic Data
Data from the CARDIoGRAMplusC4D Consortium was obtained to assess the association of rs4299376 with risk of CAD. The minor allele (LDL-C decreasing) of rs4299376 was associated with a modest yet significant decrease in risk of CAD (OR 0.95, 95% CI 0.93-0.97; P=2.85×10 −7 ). We then derived the predicted effect of 24 g/d cholestyramine on risk of CAD based on the association of the ABCG5/8 rs4299376 polymorphism on CAD, adjusting the per-allele genetic effect to match the LDL-C reducing effect of 24 g/d cholestyramine. Cholestyramine 24 g/d was predicted to significantly reduce the risk of CAD (OR 0.63, 95% CI 0.52-0.77; P=6.3×10 −6 ). The predicted estimate was not significantly different from the effect observed in the only outcome trial of cholestyramine, LRCCPPT (P for difference >0.05; Figure 6 ). The effect of rs4299376 was also matched to the LDL-C reducing effect of 3.75 g/d colesevelam, leading to a predicted CAD reduction of OR=0.64 (95% CI 0.52-0.79; P=4.3×10 −5 ) with colesevelam 3.75 g/d (P for difference >0.05; Figure 6 ).
Predicted Effect of BAS on Cardiovascular Outcomes Based on CTT Data
As a sensitivity analysis, we used estimates from the CTT to determine whether the effect of BAS on reduction of CAD event was consistent with the one observed with statins by matching the LDL-C lowering effect from LRCPPT to the reported effect from CTT, a large meta-analysis evaluating the effect of cholesterol reduction on CVD. 25 The change in LDL-C levels from 24 g/d cholestyramine was predicted to significantly decrease the risk of major vascular events (OR 0.86, 95% CI 0.85-0.87; P=6.6×10 −83
; Figure 6 ). This estimate was not significantly different from observed effect of cholestyramine from clinical trial 8 (LRCCPPT; P for difference >0.05). Similarly, the effect of 3.75 g/d colesevelam was also predicted to significantly reduce the risk of cardiovascular events (OR 0.90, 95% CI 0.87-0.93; P=1.3×10 −13 ; P for difference >0.05).
Discussion
Mendelian Randomization analyses use the random allocation of alleles to replicate the randomization process in doubleblinded clinical trials and to reduce the potential effects of reverse causation and confounding factors. The results of our Mendelian randomization analysis suggest that BAS may be effective in the prevention of CAD. Thus, when given in currently recommended doses, our data demonstrates that cholestyramine and colesevelam were associated with a reduced risk of CAD. Furthermore, our projections concerning the effect of BAS on clinical outcomes were consistent with estimates obtained from the cholestyramine LRCCPPT trial and the CTT.
The predicted effects of BAS on cardiovascular outcomes were based on robust genetic data, which was collectively derived from 194 427 participants from the CARDIoGRAMplusC4D Consortium and 95 708 participants from the Global Lipids Genetics Consortia, respectively. Leveraging already available genetic data is highly cost-effective and has the added advantage of providing estimates that reflect lifelong difference in plasma LDL-C levels between carriers and noncarriers of the rs4299376 allele. In contrast, randomized trials are complex, expensive, and are generally restricted to several years of follow-up, which limits the ability to assess the long-term effects of BAS on clinical outcomes.
Our findings have important clinical implications. Although BAS monotherapy may not be as effective as statin therapy, our results suggest that BAS are likely to be an effective second-line therapy. In contrast, adequately powered randomized trials have failed to show a benefit of Niacin and CETP inhibitors. [43] [44] [45] There has also been a shift in clinical guidelines, where patients are more likely to be prescribed with high dose statin therapy to reduce the risk of CAD irrespective of meeting specific LDL-C targets. 2 However, statin therapy may not be well-tolerated or effective in all patients, and the addition of BAS in combination with statin therapy may further prevent the risk of CAD. Even though there is clinical evidence demonstrating that cholestyramine effectively reduces LDL-C levels, as well as suggestive evidence that it decreases the risk of CAD events, its use is hampered by poor patient tolerability and adverse side effects. 6 Colesevelam is much better tolerated, 46 ,47 has other potential benefits, such as reducing fasting blood glucose levels, 48 and in our Mendelian randomization analysis produced a similar reduction in CAD to that of cholestyramine. Furthermore, our results were also supported by studies that assessed the effect of the cholesterol-lowering agent ezetimibe on CVD risk using both clinical and genetic data. For instance, the IMPROVE-IT trial demonstrated that the addition of ezetimibe to statin therapy resulted in an additional reduction in CVD risk as compared with statin therapy alone. 49 Additionally, genetic studies have also showed that mutations known to inactivate NPC1L1 were associated with lower levels of plasma LDL-C and a reduced risk of CAD. 50 Thus, our results suggest a beneficial effect of colesevelam on risk of CAD and highlight the need for well-designed RCTs to fully understand the clinical efficacy and safety of colesevelam as compared with a placebo, alone or in combination with other lipid lowering agents.
The ABCG5/8 genes and BAS act through related biological mechanisms. BAS bind to intestinal bile acids and are excreted through the feces, thus impeding the enterohepatic circulation of bile acid. This leads to an increase in bile acid synthesis and a subsequent decrease in plasma LDL-C levels. 51 Animal models have demonstrated that hepatic ABCG5/8 transporters are responsible for secreting multiple sterols in the bile, whereas intestinal transporters limit cholesterol absorption from the lumen and thus promote fecal excretion. 52, 53 Overexpression of ABCG5/8 genes in transgenic mice resulted in an increase in biliary cholesterol secretion, reduced cholesterol absorption, and increased hepatic cholesterol synthesis, 52 leading to a significant reduction in plasma cholesterol levels and atherosclerotic lesions. In addition, treatment with BAS has also been associated with reduced levels of fasting plasma glucose. 48 Although the underlying mechanism is unknown, it has been suggested that the binding of BAS to bile acids alters the GI tract glucose absorption. 54 In support of that hypothesis, studies have also indicated that gastric bypass surgery leads to an increase in glucose metabolism as a result of an increase in bile acid concentration. 55 In our study, we did not observe an association of rs4299376 SNP with the changes in the levels of fasting glucose or HbA 1c and diabetes mellitus using data from the MAGIC and DIAGRAM Consortia (P>0.05 for all), 38, 39 suggesting that this could be a beneficial pleiotropic effect specific to the pharmacological agent. Genetic mutations of ABCG5/8 have also been associated with sitosterolemia, a rare genetic disorder resulting in increased intestinal absorption, decreased biliary excretion of dietary sterols, hypercholesterolemia, and atherosclerosis. BAS treatment lowers blood levels of dietary sterols 56, 57 and is recommended for patients with sitosterolemia. Teupser et al (2010) reported that common ABCG5/8 polymorphisms lower phytosterol levels as well as CVD risk, 58 again confirming the similarity between BAS treatment and the effect of rs4299376. Taken together, these results confirm the similarity between BAS treatment and the effect of rs4299376. Therefore, our genetic results illustrate that inhibition of intestinal cholesterol absorption may provide a valuable therapeutic target for the prevention of CVD.
A few limitations of our study warrant discussion. First, Mendelian randomization analyses require some assumptions to be met for the analysis to be valid, and these include the following: the genetic variant is associated with the exposure of interest, the genetic variant is independent of confounders, and the genetic variant is independent of the outcome given the exposure and confounding factors. 12 Although the rs4299376 SNP acts through a similar functional pathway as BAS, we cannot exclude the possibility of pleiotropic effects of the genetic variant or off-target effects of the drug. For instance, both are involved in the absorption of dietary sterol, which may be a key mediator of their CAD protective effect. Second, we were unable to assess the effect of ethnicity on BAS efficacy because of the lack of reported data. Third, we found that the effect of colesevelam on triglycerides predicted by genetic data was statistically different from the pharmacological effect. Nonetheless, the predicted effect was weak (8.94 mg/dL [95% CI: 15.5, 2.32]) and should not affect CAD risk estimates because the effect size of triglycerides is modest in comparison with other CAD risk factors. 59 Furthermore, our meta-analysis may have been underpowered to detect any change because triglycerides are highly clinically variable. However, the effects on TC and HDL-C predicted from genetic data were consistent with estimates from the meta-analysis. Fourth, the protective effect of BAS on CAD was larger in the Mendelian randomization analysis as compared with the reported trend from LRCCPPT and estimates derived from the CTT. Although the differences in estimates were not statistically different, this may be because of the observation that rs4299376 carriers have a lifelong exposure to lower levels of LDL-C. Finally, the predicted side effects of BAS therapy using a Mendelian randomization analysis have not been addressed and further research may be required.
In summary, this systematic review, meta-analysis, and large-scale Mendelian randomization analysis illustrates that Figure 6 . Comparison of the effects of bile acid sequestrants (BAS) on coronary artery disease (CAD) outcomes from the Lipid Research Clinics Coronary Primary Prevention Trial (LRCCPPT) clinical trial to predicted effects using genetic data. This figure represents the point estimates with 95% confidence intervals of the effect of 24 g/d cholestyramine on CAD using clinical data from the LRCCPPT Trial, the predicted effect of 24 g/d cholestyramine on CAD using genetic data, and the predicted effect of 24g/d cholestyramine on CAD using data from the Cholesterol Treatment Trialists' (CTT). It also shows the point estimates with 95% confidence intervals of predicted effect of 3.75 g/d colesevelam on CAD using genetic data and the predicted effect of 3.75 g/d colesevelam on CAD using data from the CTT. The predicted effect of colesevelam using genetic data and CTT were compared with the LRCCPPT Trial because no outcome trial data were available for colesevelam. The predicted effect of 24 g/d cholestyramine and 3.75 g/d colesevelam were derived by standardizing the genetic estimates to match the low-density lipoprotein cholesterol (LDL-C) lowering effect of BAS. CAD is defined as one of the following: MI >50% stenosis in at least one coronary vessel at angiography, history of percutaneous transluminal coronary angioplasty, or coronary artery bypass graft surgery, angina, or death caused by CAD. 24 Diff P represents the P value for difference between the predicted BAS effect on CAD outcomes using genetic data as compared with the effect of BAS on CAD outcome from the LRCCPPT and the difference between the effect of BAS compared with the effect from the CTT Trial, respectively. RCT indicates randomized controlled trial.
pharmacological inhibition of intestinal cholesterol absorption may reduce the risk of major cardiovascular events. Comparisons of genetic association studies and clinical trials of colesevelam support the potential use of BAS as a second line therapy to reduce LDL-C in the prevention of CAD. Our results point to the need for large-scale randomized trials to fully assess the efficacy and safety of BAS treatment on CVD, as well as their effect when combined with other lipid lowering agents, such as statins.
